Home LiteratureArticle Details
PMID: 1329637 Published · ppublish English Journal Article

Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.

Antimicrobial agents and chemotherapy ·Vol. 36 ·No. 9 ·1992-09-00 ·Pages 1997-2004

Kinzig M, Sörgel F, Brismar B, Nord CE

Abstract

The pharmacokinetics of tazobactam and piperacillin in plasma and different tissues after a 30-min intravenous infusion of 4 g of piperacillin and 0.5 g of tazobactam were investigated in 18 patients who underwent elective colorectal surgery. Serial blood samples were collected for up to 6 h after the initiation of the infusion. The types of tissue collected were fatty tissue, muscle, skin, appendix, and intestinal mucosa (proximal and distal). On the basis of concentrations in plasma, the following pharmacokinetic parameter values were obtained (values are means +/- standard deviations): maximum concentration of drug in serum, tazobactam, 27.9 +/- 7.67 micrograms/ml; piperacillin, 259 +/- 81.8 micrograms/ml; time to maximum concentration of drug in serum, tazobactam, 0.51 +/- 0.03 h; piperacillin, 0.51 +/- 0.03 h; area under the concentration-time curve, tazobactam, 47.6 +/- 13.3 micrograms.h/ml; piperacillin, 361 +/- 80.3 micrograms.h/ml; clearance, tazobactam, 188 +/- 52.3 ml/min; piperacillin, 194 +/- 42.9 ml/min; half-life, tazobactam, 1.42 +/- 0.32 h; piperacillin, 1.27 +/- 0.24 h; apparent volume of distribution, tazobactam, 0.31 +/- 0.07 liter/kg of body weight; piperacillin, 0.29 +/- 0.06 liter/kg; volume of distribution at steady state, tazobactam, 0.28 +/- 0.04 liter/kg; piperacillin, 0.25 +/- 0.05 liter/kg. The concentrations of tazobactam and piperacillin in fatty tissue and muscle tissue were 10 to 13 and 18 to 30% of the levels in plasma, respectively. In skin, the concentrations of piperacillin were 60 to 95% of the levels in plasma, whereas the concentrations of tazobactam in plasma were 49 to 93% of the levels in skin tissue. The mean concentration of tazobactam in the investigated gastrointestinal tissues (appendix, proximal and distal mucosa) exceeded levels in plasma after 1 h, while piperacillin showed a mean penetration into these tissues of 43 and 53%. The mechanisms that can be used to explain the extent of penetration of piperacillin and tazobactam are discussed. Simple diffusion may take place in fatty and muscle tissue, while penetration into skin and gastrointestinal tissue is governed by more complex mechanisms which lead to differences in penetration between piperacillin and tazobactam. For all tissues investigated (except fatty tissue), the time course of the concentrations of both compounds was similar, with a peak in concentration at between 1 and 2 h after the start of infusion followed by a decline of concentrations that were almost parallel to the curves of the drug concentrations in plasma. In plasma and in all investigated tissues, piperacillin as well as tazobactam reached or exceeded the concentrations found to be effective in vitro.

MeSH Terms
Adipose Tissue/metabolism Adult Aged Chromatography, High Pressure Liquid Colon/surgery Female Half-Life Humans Infusions, Intravenous Intestinal Mucosa/metabolism Male Middle Aged Muscles/metabolism Penicillanic Acid/pharmacokinetics,therapeutic use Piperacillin/pharmacokinetics,therapeutic use Premedication Rectum/surgery Skin/metabolism Specimen Handling Tazobactam beta-Lactamase Inhibitors
Chemicals
beta-Lactamase Inhibitors Penicillanic Acid Tazobactam Piperacillin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Kinzig M
IBMP-Institute for Biomedical and Pharmaceutical Research, Nuremberg-Heroldsberg, Germany.
Sörgel F
Brismar B
Nord C E
References (15)
15 references, click to expand
  1. Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid.
    J Antimicrob Chemother. 1989 Jul;24(1):89-92 PMID: 2550415
  2. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination.
    Scand J Infect Dis Suppl. 1990;74:235-48 PMID: 2097712
  3. High-performance liquid chromatography analysis of mezlocillin, piperacillin, their degradation products, and of ioxitalamic acid in plasma and urine of healthy volunteers.
    Arzneimittelforschung. 1985;35(7):1099-104 PMID: 4052146
  4. Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Drugs. 1984 Nov;28(5):375-425 PMID: 6391888
  5. Prediction of creatinine clearance from serum creatinine.
    Nephron. 1976;16(1):31-41 PMID: 1244564
  6. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin.
    Antimicrob Agents Chemother. 1991 Jun;35(6):1081-4 PMID: 1656853
  7. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia.
    Scand J Infect Dis Suppl. 1990;74:218-34 PMID: 2097710
  8. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates.
    Chemotherapy. 1990;36(5):356-64 PMID: 2170081
  9. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Antimicrob Agents Chemother. 1989 Nov;33(11):1964-9 PMID: 2558615
  10. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):495-510 PMID: 2560422
  11. Multiple-dose pharmacokinetics of piperacillin and azlocillin in 12 healthy volunteers.
    Clin Pharm. 1986 Nov;5(11):911-6 PMID: 3780161
  12. Pharmacokinetics of piperacillin in subjects with various degrees of renal function.
    Antimicrob Agents Chemother. 1983 Jun;23(6):881-7 PMID: 6225390
  13. Pharmacokinetics of YTR830H in healthy human subjects.
    J Chemother. 1989 Jul;1(4 Suppl):505-6 PMID: 16312505
  14. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.
    Antimicrob Agents Chemother. 1978 Dec;14(6):829-37 PMID: 742871
  15. Gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers.
    Am J Med. 1989 Nov 30;87(5A):62S-65S PMID: 2589388
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1992-09-00
Pages
1997-2004
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC192425
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]